Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 19, 2022 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans

New leaders to elevate product portfolio, customer-centric commercial capabilities, and sales and marketing execution SALT LAKE CITY, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.,...
December 08, 2022 19:15 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model

SALT LAKE CITY, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today presented results from a longitudinal study...
November 29, 2022 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment

Spotlight discussion highlights how combined risk score may lead to improved breast cancer prevention and screening strategies. SALT LAKE CITY, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics,...
November 17, 2022 07:05 ET | Source: Myriad Genetics, Inc.

GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care

SALT LAKE CITY, Nov. 17, 2022 (GLOBE NEWSWIRE) -- More than 83% of primary care providers (PCPs) wish more of their patients would talk to them about mental health issues and concerns so they can...
November 14, 2022 08:00 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting

SALT LAKE CITY, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will spotlight efforts to expand access to prenatal and...
November 10, 2022 08:00 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information

UroSuite helps healthcare providers personalize treatment with easier access to biomarker, germline and somatic testing from a single source. SALT LAKE CITY, Nov. 10, 2022 (GLOBE NEWSWIRE) --...
November 03, 2022 18:00 ET | Source: Myriad Genetics, Inc.

New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries

SALT LAKE CITY, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today JCO Precision Oncology has published a...
November 01, 2022 09:10 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics and Its Market-Leading SneakPeek® Early Gender DNA Test

$67.5 million tuck-in acquisition strengthens Myriad’s Women’s Health portfolio of prenatal productsFast-growing SneakPeek test has helped 750,000 parents learn baby’s gender from home – earliest...
November 01, 2022 09:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Reports Third Quarter Financial Results

Highlights: Revenue of $156.4 million for the quarter ended September 30, 2022. Third quarter revenue, excluding divested businesses, was impacted by currency translations ($3.3...
October 31, 2022 16:30 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member

SALT LAKE CITY, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today the election of Paul M. Bisaro to its...